Myelomeningocele (MM) represents the most common congenital malformation affecting the nervous system, resulting from incomplete closure of the posterior neuropore during primary neurulation. It is observed in approximately 30 of every 100,000 live births in North America,22,46 and considerably higher in many low-resource populations, including those of sub-Saharan Africa and parts of Southeast Asia.13 Dietary supplementation with folate, an important substrate for neurulation, remains the most important public health intervention curbing the prevalence of MM in many parts of the world.36

Rationale for Prenatal Repair

Traditionally, an open neural defect is closed in the days following childbirth. By establishing a skin-covered layer above the defect, open postnatal repair mitigates the risk of meningitis and serves to achieve a suitable cosmetic result. Moreover, creating a protective plane between the neural tissue and the external environment theoretically alleviates further neurological damage to the more rostral nerve roots and spinal cord.

The widespread use of advanced prenatal ultrasonography, offering a detailed survey of neural development in utero, suggests an opportunity for preservation of function and potential reversibility of early morphological changes in the fetus diagnosed with myelomeningocele. The Management of Myelomeningocele Study (MOMS) demonstrated reduced need for shunting and improved neurological function in patients treated in utero relative to postnatally, thereby offering level 1 evidence supporting fetal repair. Subsequent studies have offered additional information about urological, orthopedic, radiological, and maternal factors surrounding fetal repair. The quest for robust long-term neurocognitive and motor function data is underway and poised to shape the future of fetal repair. In addition, technical innovations such as fetoscopic surgery aim to minimize maternal morbidity while conferring the beneficial effects observed with open intrauterine intervention.

https://thejns.org/doi/abs/10.3171/2019.4.PEDS18383

KEYWORDS fetal; fetoscopic; intrauterine; myelomeningocele; spina bifida; congenital
The benefits observed must be weighed against several risks associated with fetal surgery. The prenatal group was delivered significantly earlier (34.1 vs 37.3 weeks, p < 0.001), and severe prematurity (< 30 weeks) was observed in 13% of prenatal patients compared with no patients in the postnatal cohort. Chorionic membrane separation, premature rupture of membranes (PROM), spontaneous membrane rupture, spontaneous preterm labor, and oligohydramnios all occurred with greater frequency in months of age with physical and neurological examinations and development assessments. The first primary outcome, at 12 months, was a composite of death or the need for a CSF shunt. Both adjudicated and actual proportions were reported. The second primary outcome was mental development and motor function at 30 months. Secondary outcomes included maternal surgical and pregnancy-related complications, as well as child functional disability and presence and degree of CM-II findings.

Technique

The MM closure technique was standardized across centers, and at the time represented the customary intrauterine closure method. After creation of an adequately sized hysterotomy by the fetal surgery team, the fetus was administered an intramuscular injection of fentanyl and vecuronium. The neurosurgeon sharply incised the neural placode from the surrounding tissue to allow the neural contents to descend into the canal. Next, the dura was incised circumferentially and reflected over the defect and closed with fine running suture. While these early data suggested a possible benefit to the fetus, major questions remained, including those regarding perioperative fetal health, maternal safety, and implications of fMMR on subsequent pregnancies, among others.

The Management of Myelomeningocele Study

Methods

Built upon findings from the aforementioned animal and preclinical human studies, the Management of Myelomeningocele Study (MOMS) sought to prove the efficacy and safety of IUR with level 1 evidence. This was a prospective, randomized clinical trial comparing prenatal versus postnatal closure at three geographically disparate centers: Vanderbilt University Medical Center, the University of California, San Francisco, and Children’s Hospital of Philadelphia (CHOP). Upon prenatal diagnosis of MM, mothers were referred to one of these three centers where-inclusion and exclusion criteria were applied. During the trial, there was a moratorium on nontrial centers. Candidates included singleton pregnancies between 19 and 26 weeks of gestation, without unrelated fetal anomalies or an abnormal placenta. Mothers were excluded if they were morbidly obese (BMI > 35 kg/m²) or had other comorbidities deemed potentially harmful to the fetus (HIV-positive, poorly controlled hypertension), lacked the requisite psychosocial support, or were unable to relocate to one of the trial centers.

Mothers randomized to the treatment arm underwent intrauterine closure before 26 weeks’ gestation and remained near the fetal surgery center until 37 weeks, when the child was delivered by cesarean section. Mothers in the postnatal arm sought routine prenatal care at home and then returned to the fetal surgery center at 37 weeks for a scheduled cesarean section. The same neurosurgical team then performed the postnatal MM repair within 48 hours of delivery. Children were followed up at 12 and 30

In the treatment arm, the fetal MM repair was performed via an endoscopic approach in the early 1990s in several centers in the US and Europe. Dismal results in these early series shifted the field toward open techniques, such that by the end of the millennium, several institutions produced more encouraging data for fMMR. Investigators at Vanderbilt University and Children’s Hospital of Philadelphia demonstrated that patients treated via open fMMR displayed less hindbrain herniation and a normalization of CSF dynamics, which resulted in a reduction of postnatal shunting procedures. While these early data suggested a possible benefit to the fetus, major questions remained, including those regarding perioperative fetal health, maternal safety, and implications of fMMR on subsequent pregnancies, among others.

Results: Primary and Secondary Outcomes

MOMS enrollment was terminated early due to efficacy in the prenatal arm, after 187 of the originally planned 200 patients were randomized. Both primary outcomes were positively influenced. The actual rate of shunt placement was 40% in the prenatal surgery group relative to 82% in the postnatal surgery group (p < 0.001). The adjudicated rate was 68% and 98%, respectively (p < 0.001). Radiographic findings at the 12-month follow-up were also more favorable in the prenatal surgery group, showing lesser degrees of hindbrain herniation, brainstem kinking, and syringomyelia observed relative to the postnatal group. In addition, the composite outcome of the Bayley Mental Development Index and motor level improvement at 30 months were better in the prenatal surgery group (p = 0.007). It is important to note that the statistical difference in this outcome is driven by the motor improvement and not the Bayley Mental Development Index scores. Patients treated prenatally were more likely to have a level of function two or more levels better than expected according to anatomical level (32% vs 12%, p = 0.005), despite having more severe lesions than their postnatally treated counterparts.

Drawbacks

The benefits observed must be weighed against several risks associated with fetal surgery. The prenatal group was delivered significantly earlier (34.1 vs 37.3 weeks, p < 0.001), and severe prematurity (< 30 weeks) was observed in 13% of prenatal patients compared with no patients in the postnatal cohort. Chorionic membrane separation, premature rupture of membranes (PROM), spontaneous membrane rupture, spontaneous preterm labor, and oligohydramnios all occurred with greater frequency in
the prenatal arm. Maternal risks were also greater following fetal surgery, i.e., pulmonary edema and the need for blood transfusion were more common among women in the prenatal cohort. Lastly, all mothers are counseled that future pregnancies must be delivered by cesarean section to avoid the risk of uterine dehiscence and rupture.

**After MOMS**

**MOMS Cohort Subanalyses**

Since publication of the early-terminated trial results, several analyses have been conducted on the full MOMS cohort to ascertain the influence of prenatal repair on CSF circulatory, functional, urological, and maternal outcomes. Tulipan et al. updated the results using the entire randomized cohort of 183 patients and found that the primary outcome (fetal/infant death, CSF shunting, or meeting prespecified criteria for a shunt) occurred in 73% of infants in the prenatal group relative to 98% in the postnatal group (p < 0.001). Actual rates of shunt placement, however, more closely reflected the MOMS findings: 44% versus 84% in the two groups. The difference between these sets of figures appeared to hinge on the portion of the shunting criteria detailing overt signs and symptoms.
of hydrocephalus, i.e., a bulging fontanelle, split sutures, or sunsetting eyes. When these were not present, the predetermined criteria were less likely to be followed in the decision to place a CSF shunt. Another important finding was that among the prenatal cohort, fetal ventricle size at prenatal screening, as measured by atrial diameter, correlated with the need for postnatal shunt insertion. Twenty percent of those with a ventricle size < 10 mm required a shunt, relative to 79% of those with a ventricle size > 15 mm. Among the postnatal group such a dramatic difference was not observed, as more than 80% of patients required a shunt irrespective of ventricle size. Finally, a ventriculoperitoneal (VP) shunt placed in a patient with prenatal repair appeared to be more durable, requiring a revision at less than half the rate as one placed in a postnatal patient. The authors concluded that caution should be taken when advising the family of a patient with enlarged ventricles (> 15 mm), as a primary benefit to IUR (shunt freedom) appears to disappear in this subpopulation.

Because the trial was stopped early for efficacy, the MOMS flagship publication only included 30-month outcomes for 134 of the 183 randomized mother-child dyads. In a second analysis of the MOMS cohort for 30-month outcomes by Farrer et al. in 2018, inspection of the full cohort of patients supported the original observations: prenatal repair improves motor development and reduces the rate of permanent CSF diversion.14 No relationship was drawn between postnatal motor function and prenatal ventricular size. Therefore, the authors concluded that outcomes related to CSF diversion should be treated separately from those of distal neurological function during prenatal counseling for potential intrauterine surgery.14

Additional topic-specific subanalyses of the MOMS data in 2015 and 2016 revealed that the rate of clean intermittent catheterization was not different between the two groups; however, among the prenatal cohort there was less bladder trabeculation and open bladder neck.3 Obstetric complications associated with prenatal surgery were confirmed on close inspection of the entire MOMS cohort. Early gestational age at surgery and chorioamnion membrane separation were associated with spontaneous membrane rupture. In addition, oligohydramnios was found to be a risk factor for preterm delivery.20

Post-MOMS Clinical Studies

Since the landmark MOMS publication, several groups have reported their post-MOMS patient outcomes, providing insight on what fetal surgery for MMC is like for off-trial patients. The first such publication was from Vanderbilt in 2014 comparing 43 patients who underwent fMMR at Vanderbilt to the MOMS prenatal cohort.3 The goal of this study was to evaluate a modification to the uterine opening in an effort to reduce amniotic membrane separation and other related maternal complications. Improved maternal outcomes were observed relative to the original trial cohort. The incidence of PROM was reduced by half (22% vs 46%, p = 0.011) and chorioamnion separation was eliminated altogether (0% vs 26%, p < 0.001). Adjustments in the surgical technique also correlated with prolonged gestation. Nearly twice as many babies were born at term (39% vs 21%, p = 0.03), and only 4% were born earlier than 30 weeks compared with 13% of the MOMS cohort (p = 0.084). Forty-one percent of patients required VP shunting, similar to the original trial (40%).2,3

The following year, the largest cohort of patients post-MOMS was reported from CHOP describing 100 consecutive fMMRs and their postoperative course.32 Among the 587 mothers referred to this high-volume center between 2011 and 2014, 101 (17%) were taken to the operating room for IUR. The most common reasons for exclusion were the discovery of additional anomalies on imaging, preexisting maternal medical condition, and declining the on-site prenatal appointment (11% each). Maternal BMI > 35 kg/m2 was uncommon (2%), and termination of pregnancy occurred in a minority of patients referred for fMMR (7%). The gestational age at the time of surgery was 23.3 weeks, or 1 week earlier than the MOMS cohort. The average gestational age at delivery was 34.3 weeks and 54% of babies were born at 35 weeks or later, both figures essentially matching those in the MOMS trial patients. Maternal complications were slightly lower than in MOMS, suggesting a learning benefit as well as improvements in the surgical proceedings. Relative to MOMS, the CHOP post-MOMS patients were less likely to experience membrane separation (23% vs 26%), PROM (32% vs 46%), oligohydramnios (6% vs 21%), and maternal transfusion (3% vs 9%). Preterm labor was equivalent between groups (37% vs 38%). Importantly, there were 6 prenatal deaths (6%) in the post-MOMS group compared to the 2 (3%) in the MOMS trial. The overall rate of shunting was not reported in this cohort, although 17% of patients with imaging demonstrated no evidence of hindbrain herniation postnatally. Fifty-five percent of patients undergoing a postnatal physical evaluation were assigned a functional level that was one level or more better than that determined by prerepair anatomical level.32

Inclusion Cysts and Spinal Cord Tethering

As with postnatal MMC closure, inclusion cysts and spinal cord tethering are important complications that can arise following fetal repair.10,28 While the incidence of symptomatic tethered cord syndrome (TCS) following postnatal repair is approximately 10%–13%,18,39 as many as a third (33%) of fMMR patients may experience this condition.11 It is notable that inclusion cysts (such as dermoids and epidermoids) are found in the majority of fMMR patients who present with signs and symptoms of TCS.11 Unresected epithelial tissue from the transitional zone surrounding the placode may be the source of these inclusion cysts.27 Accordingly, the technical challenge of removing all such epithelia during intrauterine surgery relative to postnatal repair may form the basis for the increased incidence. Whether multilayer closure, dural or dermal substitute grafting, suture type, and/or endoscopic approach influence the rate of inclusion cyst formation or tethering remains an active area of study. It is generally believed among fetal surgeons that the incidence of inclusion cysts decreases with experience over time, due to both the experience of individual surgeons becoming more accustomed to the procedure and the growing field performing open fMMR.
Quality of Child Life and Long-Term Development

Until recently, little has been understood about long-term outcomes following fMMR. As pre-MOMS patients have begun to approach late childhood and early adolescence, higher-level neurofunctional assessments can be administered. Among 42 children treated at CHOP pre-MOMS, Danzer and colleagues found that the vast majority (nearly 80%) were community ambulators at a median follow-up of 10 years, while 14% were wheelchair bound. Normal bladder function was present in 25% of patients. The need for shunting correlated with worse behavioral adaptive skills, while the need for tethered cord release surgery was associated with deterioration of motor skills. Importantly, early neurofunctional and ambulatory status predicted long-term neurocognitive scores and motor function.

Our center recently administered quality of life assessments to our pre-MOMS fMMR cohort, all between 14 and 19 years of age, and compared them to a control sample of postnatally treated patients of the same epoch. Fewer patients in the prenatal group required future neurosurgical procedures (VP shunting, tethered cord release, etc.) than their postnatal counterparts. Additionally, patients who underwent fetal repair scored higher on the psychosocial health assessment and total quality of life assessment than the postnatal controls. Interestingly, physical health scores were similar between the two groups.

The MOMS II study is designed to address these questions with greater rigor. Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, this study evaluates children from the original MOMS cohort now aged 5 to 8 years old (NIH NICHD grant no. 5U01HD068541-05). Adaptive behavior, cognitive functioning, motor level and function, and urological health are all assessed, along with brain morphology and connectivity using high-resolution imaging. In addition to child health, quality of life, maternal health, and family impact are all measured in this study, which is expected to be published in the near future.

It is important to emphasize the ongoing work by the North American Fetal Therapy Network (NAFTNet), a voluntary consortium currently consisting of 31 centers that specialize in complex disorders of the fetus. This group studies multiple problems of the developing fetus, not limited to spina bifida. However, a primary focus is a prospective database involving fMMR across North America among member institutions. With the ever-increasing numbers of fetal surgery centers, it is critical that prospective data be collected so that best practice can be determined and promulgated throughout the field.

Shifting Attitudes of Hydrocephalus Treatment

Since MOMS, there has been a growing cultural pivot in attitudes regarding shunt placement, in both parents and pediatric neurosurgeons. It may be argued that this change was brought on by MOMS itself, as parent and surgeon alike were forced to decide what constituted the need for shunt placement and, therefore, failure of the primary outcome of MOMS. This is made clear by the discrepancy in those meeting shunt placement criteria and those actually receiving a shunt. As noted previously in the Tulipan et al. follow-up study on the MOMS cohort, when the shunt criteria were not followed, it was because of the lack of physical signs of hydrocephalus such as a bulging fontanelle, split suture, or sunsetting eyes. Indeed, surgeons in the Hydrocephalus Clinical Research Network found these signs critical when making decisions in the treatment of very low-birth-weight infants with intraventricular hemorrhage of prematurity.

 Shortly after this relaxed shunt placement criteria came the increasing popularity of endoscopic third ventriculostomy (ETV) and choroid plexus catarization (CPC) for the treatment of hydrocephalus presenting for various reasons in infancy. A significant additional cultural shift began specific to the perception of appropriate ventricular size for intervention. When should we treat patients with ventriculomegaly? When should we take them back for a repeat ETV/CPC? Is the true measure of size change best performed via z-score, frontooccipital horn ratio, or brain volume? This change in willingness to accept larger ventricular size also has made an impact on not only initial treatment for hydrocephalus, but also which of the two options are considered. Often parents are more likely to accept a procedure that is not “the shunt.”

A cynic would say that the benefit of the reduced incidence of CSF diversion provided by fMMR in MOMS is mitigated by these complex cultural changes over the ensuing decade. However, the authors choose to believe that the implementation of fetal surgery for spina bifida, at least as specific to symptomatic hydrocephalus alone, is one part of an overall treatment approach that began with folic acid fortification, and continues with fetal surgery in appropriately identified patients, the incorporation of a more reserved approach in the decision to treat ventriculomegaly, and involving the initial use of ETV/CPC where appropriate.

Emerging Surgical Techniques and Future Perspectives

Beyond optimizing surgical techniques to reduce uterine-related complications, improvements in the spinal defect closure technique have also been described since the MOMS trial. Frequently, fetal dura is too thin and tenuous to serve as the only reliable barrier beneath an often-stretched skin layer. Using needlepoint electrocautery, Moldenhauer and Adzick at CHOP now create two membrane-lined myofascial flaps beyond the dura, and suture them together in the midline for a thicker, tension-free spinal canal covering. As the number of centers performing fMMR has grown, so have the variations on closing the defect. Specifically, there are several different schools of thought on dural primary closure versus onlay, muscle and fascia mobilization, and management of a defect too wide for primary closure. At this time, there is no evidence that any one way is superior to the other.

Fetal MM Closure as Performed at the Fetal Center at Vanderbilt

The patient is admitted 1 day prior to surgery, when preoperative laboratory samples are drawn and an ultrasound examination is conducted to demonstrate estimated
fetal weight and position. The anesthesia and obstetric teams evaluate and give final clearance for surgery. The fetal surgical team consists of maternal fetal medicine, pediatric neurosurgery, neonatology, pediatric cardiology, plastic surgery, anesthesia, operating room technicians, nurses, and sonographers (Fig. 2).

After a combination of general and epidural anesthesia is administered, the uterus is exposed via a vertical incision from the pubis to just above the umbilicus. The fetus and placenta are located via ultrasound and a 6- to 8-cm hysterotomy incision is created, based on avoiding the placenta and proximity of the MM sac. Meticulous care is given to suturing the uterine lining up to the opening within the uterus and minimizing direct trauma to these membranes during the intrauterine portion of the procedure.3 The fetus is administered fentanyl and vecuronium and undergoes continuous echocardiographic monitoring throughout the procedure (Fig. 3).

Under loupe magnification, the placode is sharply incised, allowing the neural contents to descend within the canal (Fig. 4). Most commonly, a synthetic dural substitute is onlaid and the focus moves to skin closure. Occasionally if the dura is judged to be substantial enough for a watertight closure, it is closed as a separate layer. The skin is mobilized and if there is not a sufficient amount of tissue for an adequate closure, an early decision is made for at least a single relaxing flank incision in order to create a bipediced skin flap. This then allows a tensionless primary closure with a running absorbable monofilament directly over the defect. Using the same suture type, an acellular dermal allograft is then sewn into the flank incisions in a running fashion. After delivery, it is noted that this tissue is often either incorporated into the surrounding skin or quickly sloughed off to reveal well-healing granulation tissue beneath. The uterus is then closed in layers followed by abdominal fascia and skin closure. The patient recovers in the obstetric postsurgical unit and a cesarean section is scheduled for 37 weeks.

**Fetoscopic Surgery**

With advancements in minimally invasive techniques and endoscopic capabilities, fetoscopic repair of MMC has begun to garner attention. In theory, the mother stands to benefit from the avoidance of a large abdominal incision and minimization of uterine scarring. Moreover, if fetoscopy can mitigate membrane rupture rates, the fetus may sustain a longer gestation period. Endoscopy for fetal dysraphism is not new, having been pioneered at Vanderbilt first in animal models in 1993.9 Indeed, the first fMMR surgery in a human was performed endoscopically—not open—in 1994 by means of a maternal graft onlay.6

However, initial results in humans were disappointing. Among the first 4 patients treated endoscopically by Bruner and colleagues, 2 died perinatally and the other 2 required a postnatal wound revision and shunt.6 In a report by Farmer et al. from 2003, 2 of 3 patients died following endoscopic repair, leading the authors to suggest that minimally invasive fMMR would be unethical until improved upon and validated in clinical trials.15
As a result, fetoscopic approaches were largely abandoned until the MOMS results were published, and innovative methods were refocused on minimizing maternal morbidity and optimizing future pregnancies. Earlier, Kohl and colleagues had described a percutaneous fetal procedure first in sheep and then in humans in which a synthetic patch is placed over the spinal defect, thus protecting the neural elements from caustic intraamniotic fluids. However, this technique mandated formal skin closure in the postnatal setting. By 2012, this group had improved their technique to include suturing of an absorbable patch over the defect followed by skin approximation with synthetic graft supplementation. In their series of 19 patients, neurological function (motor/sensory level, muscle density) was improved relative to postnatally treated controls. However, 3 (16%) suffered fetal demise, 3 (16%) had iatrogenic hemorrhage and procedural termination, and the same obstetric complications (PROM, chorioamnionitis, oligohydramnios) observed in open fetal repair were observed here. In 2016, Pedreira et al. published their series of 10 patients treated with endoscopic placement of a biocellulose patch followed by single-layer skin closure. While feasibility was demonstrated, the overall results were not favorable: 2 patients (20%) died, PROM occurred in all cases, and gestational age at birth was nearly 2 weeks earlier than those of the MOMS prenatal cohort (32.4 vs 34.1 weeks). Onlay patches with variable degrees and methods of securement, while technically simpler than primary dural closure, appeared to result in less favorable wound results and persistent maternal morbidity; the so-called “patch-and-glue” technique lost traction.

More recently, Whitehead and colleagues at Texas Children’s Hospital have pioneered an endoscopic multi-layer closure designed to retain the maternal advantages of minimal uterine manipulation offered by endoscopy while also minimizing CSF and wound complications associated with nonsutured graft closures. In this two-port technique, a patch graft is placed over the circumferentially incised and descended placode. A dura/fascial flap is created on either side of the spinal canal and, along with the overlying skin, reapproximated with interrupted sutures. In a preliminary report of the first 12 cases using this closure technique, 70% of infants were born vaginally and there were no cases of uterine dehiscence. Twenty-five percent experienced PROM and were born less than 37 weeks' gestational age. Surgical time, however, was lengthy (mean

**FIG. 3.** Fetal exposure. Under sonographic guidance the hysterotomy is planned to optimize exposure of the spinal defect while protecting the placenta, umbilical cord, and other relevant fetal anatomy (A). The uterus is entered with electrocautery, the membrane is opened, and full-thickness running locked sutures secure the membrane to the uterine wall (B). Fetal cardiac monitoring is used throughout the case, with continuous communication between pediatric cardiology and anesthesia (C and D). Figure is available in color online only.
243 minutes), most of which was required for neural tube defect closure (mean 141 minutes). In this minimally invasive, multilayer technique, there were no CSF leaks or need for wound revisions, while 90% saw reversal of hindbrain herniation and the vast majority (80%) demonstrated a functional level improvement. While early results are intriguing, validation from larger cohorts across multiple centers is needed before the fetoscopic method can be considered among the standards for fMMR.

Further Technical Innovation

It would be remiss to not speculate on continued technical innovations for in utero surgery application. Currently, spina bifida is the only nonlethal disease for which fetal intervention is offered. As applicability increases, there will be more opportunity for instrument and platform adaptation. For example, the use of endoscopy is purported to enable mothers to return to a vaginal delivery for the subsequent child with a decreased risk of uterine rupture or fetal demise. The pivot to a focus on vaginal delivery and successful subsequent pregnancies reflects the positive outcomes for children not only in hydrocephalus and neurological function, but also in reducing the incidence of preterm delivery. The initial fetoscopic work had challenging outcomes and there were issues with wound healing, resulting in returns to the operating room after delivery as well as fetal demise. This improved over time, with experience. There are limitations of the endoscopic technique, specifically the lack of instrument wrist articulation and dexterity at the point of interface with the patient. The surgical robot, used for years by general and urological surgeons for intracavitary procedures, is designed to overcome these types of issues. Several centers have begun to experiment with robotic intrauterine surgery simulations, including Vanderbilt. It is the opinion of the authors that this will be the most likely next step in fetal surgery innovation.

Conclusions

Intrauterine surgery for spina bifida has been a quarter-century journey. The early pioneers of the procedure deserve great credit for overcoming both the procedural challenges and the naysayers who felt the risk outweighed the benefit. However, without the early criticism and doubt, it is unlikely a trial such as MOMS would have commenced. What started with early investigations prompting an NIH-funded multicenter trial has now grown to include over 15 centers across North America and the world that perform fMMR. Each year, more centers are offering fMMR. Recent growth of the entire specialty of fetal medicine dedicated to caring for women with fetal neurological anomalies is largely due to this relatively rapid procedural climatization.

There is unlikely to be another study on this topic of the magnitude of MOMS. Whether one argues that the shunting culture of today or advent of ETV/CPC mitigates the findings of MOMS in any way, or that the indications for fetal surgery for spina bifida should be expanded, it is difficult to argue its impact on our field. The original MOMS cohort will continue to be studied on a longer-term basis.
for the primary and secondary outcomes, as well as teth-
ering, urinary function, and quality of life. As pediatric
neurosurgeons, crucial to the overall effort, we must criti-
cally examine the modifications to the original procedure
in order to define and disseminate best practices. Then we
must begin that process again. As more centers gain ex-
pertise, opportunities for innovation should increase, not
wane. The field should not be content with the outcomes of
today, however improved they are compared with the early
days of fMR. Our goal for the patient receiving a pre-
natal diagnosis of spina bifida should be the elimination
of hydrocephalus, normalization of neurological function,
term delivery for the infant, and the ability of the mother
to return to a normal risk for subsequent pregnancy.

References

1. Adzick NS, Sutton LN, Crombleholme TM, Flake AW: Suc-

2. Adzick NS, Thom EA, Spong CY, Brock JW III, Burrows
PK, Johnson MP, et al: A randomized trial of prenatal ver-
364:993–1004, 2011

3. Bennett KA, Carroll MA, Shannon CN, Braun SA, Dabrow-
-kaucka ME, Crum AK, et al: Reducing perinatal complications
and preterm delivery for the infant, and the ability of the mother
to return to a normal risk for subsequent pregnancy.

4. Bouchard S, Davey MG, Rintoul NE, Walsh DS, Rorke LB,

5. Brock JW III, Carr MC, Adzick NS, Lawrence D, Aryanpur J,

coverage of fetal myelomeningocele in utero. Am J Obstet
Gynecol 180:153–158, 1999

7. Bruner JP, Tulipan N, Paschall RL, Boehm FH, Walsh WF,
Silva SR, et al: Fetal surgery for myelomeningocele and the
incidence of shunt-dependent hydrocephalus. JAMA
282:1819–1825, 1999

of fetal open myelomeningocele in utero. Am J Obstet Gy-
ecol 176:256–257, 1997

9. Copeland ML, Bruner JP, Richards WO, Sundell HW, Tulip-

10. Danzer E, Adzick NS, Rintoul NE, Zarnow DM, Schwartz
ES, Melchionni J, et al: Intradural inclusion cysts fol-

11. Danzer E, Thomas NH, Thomas A, Friedman KB, Gerdes M,
functioning, and behavioral adaptive skills following fetal
myelomeningocele surgery. Am J Obstet Gynecol 214:269,
e1–269.e12, 2016

B, et al: Comparison of hydrocephalus metrics between in-
fants successfully treated with endoscopic third ventriculos-
tomy with choroid plexus cataractization and those treated
with a ventriculoperitoneal shunt: a multicenter matched-cohort

13. Dewan MC, Rattani A, Mekary R, Glanzc LJ, Yunusa I,
Baticulon RE, et al: Global hydrocephalus epidemiology and
incidence: systematic review and meta-analysis. J Neurosurg
130:1065–1079, 2019

Study: full cohort 30-month pediatric outcomes. Am J Ob-
stet Gynecol 218:256.e1–256.e13, 2018

N, Lee H, et al: In utero repair of myelomeningocele: ex-
perimental pathophysiology, initial clinical experience, and

paralysis associated with myelomeningocele: clinical and ex-
perimental data implicating a preventable spinal cord injury.
Neurosurgery 26:987–992, 1990

17. Heffez DS, Aryanpur J, Rotellini NA, Hutchins GM, Free-
man JM: Intrauterine repair of experimental surgically cre-
a ted dysraphism. Neurosurgery 32:1005–1010, 1993

18. Herman JM, McLone DG, Storrs BB, Dauser RC: Analysis of
153 patients with myelomeningocele or spinal lipoma opera-
ted upon for a tethered cord. Presentation, management and out-

19. Heuer GG, Adzick NS, Sutton LN: Fetal myelomeningocele
closure: technical considerations. Fetal Diagn Ther 37:166–
171, 2015

20. Johnson MP, Bennett KA, Rand L, Burrows PK, Thom EA,
Study: obstetrical outcomes and risk factors for obstetrical
complications following prenatal surgery. Am J Obstet Gy-

21. Johnson MP, Sutton LN, Rintoul N, Crombleholme TM,
Flake AW, Howell LJ, et al: Fetal myelomeningocele re-

22. Joyceu L, Danzer E, Flake AW, Depret J: Fetal surgery
for spina bifida aperta. Arch Dis Child Fetal Neonatal Ed
103:F589–F595, 2018

23. Kohl T, Hartlage MG, Kiechitz D, Westphal M, Buller T,
Achenbach S, et al: Percutaneous fetoscopic patch coverage
of experimental lumbosacral full-thickness skin lesions in

24. Kohl T, Hering R, Heep A, Schaller C, Meyer B, Greive C,
et al: Percutaneous fetoscopic patch coverage of spina bifida
aperta in the human—early clinical experience and potential.
Fetal Diagn Ther 21:185–193, 2006

25. Kohl T, Tchatcheva K, Merz W, Wartenberg HC, Heep A,
Müller A, et al: Percutaneous fetoscopic patch closure of hu-
man spina bifida aperta: advances in fetal surgical techniques
may obviate the need for early postnatal neurosurgical inter-

brain analysis in neurosurgery: Part 2. Brain and CSF vol-
umes discriminate neurocognitive outcomes in hydrocepha-

27. Martínez-Lage JF, Ruiz-Espejo Vilar A, Almagro MJ, Sán-
chez del Rincón I, Ros de San Pedro J, Felipe-Murcia M, et
al: [Spinal cord tethering in myelomeningocele and lipom-
eningocoele patients: the second operation.] Neurocirugía
(Astur) 18:312–319, 2007 (Spanish)

28. Mazzola CA, Albright AL, Sutton LN, Tuite GF, Hamilton
RL., Pollack IF: Dermoid inclusion cysts and early spinal cord
tethering after fetal surgery for myelomeningocele. N Engl J

29. Meuli M, Meuli-Simmen C, Hutchins GM, Yingling CD,
Hoffman KM, Harrison MR, et al: In utero surgery rescues
neurological function at birth in sheep with spina bifida.

30. Michejda M: Intrauterine treatment of spina bifida: primate

31. Moldenhauer JS, Adzick NS: Fetal surgery for myelomenin-

J Neuropediatr Volume 24 • August 2019 113


41. Sutton LN, Adzick NS, Bilaniuk LT, Johnson MP, Crombleholme TM, Flake AW: Improvement in hindbrain herniation demonstrated by serial fetal magnetic resonance imag-

ing following fetal surgery for myelomeningocele. *JAMA* 282:1826–1831, 1999


**Disclosures**

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

**Author Contributions**

Conception and design: both authors. Acquisition of data: both authors. Analysis and interpretation of data: both authors. Drafting the article: both authors. Critically revising the article: both authors. Reviewed submitted version of manuscript: both authors. Approved the final version of the manuscript on behalf of both authors: Dewan. Administrative/technical/material support: both authors. Study supervision: both authors.

**Correspondence**

Michael C. Dewan: Vanderbilt University, Nashville, TN. michael.dewan@vumc.org.